These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31392202)

  • 41. Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease.
    Jevnikar M; Kodric M; Cantarutti F; Cifaldi R; Longo C; Della Porta R; Bembi B; Confalonieri M
    Mol Genet Metab Rep; 2015 Dec; 5():67-71. PubMed ID: 28649546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. White matter lesions in treated late onset Pompe disease are not different to matched controls.
    Schneider I; Hensel O; Zierz S
    Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New Insights into Gastrointestinal Involvement in Late-Onset Pompe Disease: Lessons Learned from Bench and Bedside.
    Korlimarla A; Lim JA; McIntosh P; Zimmerman K; Sun BD; Kishnani PS
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
    Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
    Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease.
    Lim JA; Yi H; Gao F; Raben N; Kishnani PS; Sun B
    Mol Ther Methods Clin Dev; 2019 Mar; 12():233-245. PubMed ID: 30809555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DeepNEU: Artificially Induced Stem Cell (aiPSC) and Differentiated Skeletal Muscle Cell (aiSkMC) Simulations of Infantile Onset POMPE Disease (IOPD) for Potential Biomarker Identification and Drug Discovery.
    Esmail S; Danter WR
    Front Cell Dev Biol; 2019; 7():325. PubMed ID: 31867331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease.
    Hordeaux J; Dubreil L; Robveille C; Deniaud J; Pascal Q; Dequéant B; Pailloux J; Lagalice L; Ledevin M; Babarit C; Costiou P; Jamme F; Fusellier M; Mallem Y; Ciron C; Huchet C; Caillaud C; Colle MA
    Acta Neuropathol Commun; 2017 Sep; 5(1):66. PubMed ID: 28874182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of enzyme replacement therapy (ERT) for treatment of infantile-onset Pompe disease (IOPD) in the Iranian pharmaceutical market.
    Hashempour R; Davari M; Pourreza A; Alaei M; Ahmadi B
    Intractable Rare Dis Res; 2020 Aug; 9(3):130-136. PubMed ID: 32844068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.
    Puzzo F; Colella P; Biferi MG; Bali D; Paulk NK; Vidal P; Collaud F; Simon-Sola M; Charles S; Hardet R; Leborgne C; Meliani A; Cohen-Tannoudji M; Astord S; Gjata B; Sellier P; van Wittenberghe L; Vignaud A; Boisgerault F; Barkats M; Laforet P; Kay MA; Koeberl DD; Ronzitti G; Mingozzi F
    Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Swallow Prognosis and Follow-Up Protocol in Infantile Onset Pompe Disease.
    Swift G; Cleary M; Grunewald S; Lozano S; Ryan M; Davison J
    JIMD Rep; 2017; 33():11-17. PubMed ID: 27344650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease.
    Li RJ; Ma L; Drozda K; Wang J; Punnoose AR; Jeng LJB; Maynard JW; Zhu H; Pacanowski M
    AAPS J; 2023 Jan; 25(1):16. PubMed ID: 36653728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.
    Witkowski G; Konopko M; Rola R; Ługowska A; Ryglewicz D; Sienkiewicz-Jarosz H
    Neurol Neurochir Pol; 2018 Aug; 52(4):465-469. PubMed ID: 29803406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study.
    Peng SS; Hwu WL; Lee NC; Tsai FJ; Tsai WH; Chien YH
    Orphanet J Rare Dis; 2016 May; 11(1):63. PubMed ID: 27183828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.
    Keeler AM; Zieger M; Todeasa SH; McCall AL; Gifford JC; Birsak S; Choudhury SR; Byrne BJ; Sena-Esteves M; ElMallah MK
    Hum Gene Ther; 2019 Jan; 30(1):57-68. PubMed ID: 29901418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme.
    Pascual SI
    Adv Exp Med Biol; 2009; 652():39-46. PubMed ID: 20225018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.